Zhen Su: Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach

Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn:

“Overcome PD-1 resistant in solid tumor with a novel dual T-cell agonist approach.

We are presenting our clinical data at ESMO IO 2024 in Geneva, Switzerland next week.

I look forward to meeting friends, collaborators and oncology colleagues to share our clinical trial Phase I learning of Invikafusp Alfa (STAR0602), a first-in-class selective dual T-cell agonist for the treatment of PD-1 resistant solid tumors.